Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Abstract

In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

Keywords

OsimertinibLung cancerMedicineCancer researchOncologyInternal medicineCancerEpidermal growth factor receptorErlotinib

MeSH Terms

AcrylamidesAdultAgedAged80 and overAniline CompoundsAntineoplastic AgentsCarcinomaNon-Small-Cell LungChemotherapyAdjuvantDisease-Free SurvivalDouble-Blind MethodErbB ReceptorsFemaleHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedMutationNeoplasm RecurrenceLocalNeoplasm StagingPneumonectomyProtein Kinase Inhibitors

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network

Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA ...

2014 Nature 5605 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 18
Pages: 1711-1723
Citations: 1609
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1609

OpenAlex

Influential

1435

CrossRef

Cite This

APA Style

                            
                                
                                    Yi‐Long Wu, 
                                
                                    Masahiro Tsuboi, 
                                
                                    Jie He
                                
                                et al.
                            
                            (2020). 
                            Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer. 
                            New England Journal of Medicine
                            , 383
                            (18)
                            , 1711-1723.
                            https://doi.org/10.1056/nejmoa2027071
                        

Identifiers

DOI: 10.1056/nejmoa2027071
PMID: 32955177

Data Quality

Data completeness: 90%